Twist Bioscience (NASDAQ:TWST) Stock Gets Price Target Trim from Robert W. Baird

Twist Bioscience (NASDAQ:TWST – Free Report) had its price objective decreased by Robert W. Baird from $187.00 to $135.00 in a report issued on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

TWST has been the topic of a number of other research reports. UBS Group began coverage on Twist Bioscience in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Jefferies Financial Group assumed coverage on shares of Twist Bioscience in a research report on Thursday, October 8th. They set a “hold” rating and a $150.00 price objective for the company. Barclays increased their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, Canaccord Genuity Group decreased their target price on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating on the stock in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $141.00.

View Our Latest Report on Twist Bioscience

Twist Bioscience Stock Performance

NASDAQ TWST opened at $111.60 on Friday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $219.71. The firm has a 50-day moving average price of $150.23 and a two-hundred day moving average price of $93.07. The company has a market capitalization of $7.00 billion, a P/E ratio of -53.40 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. The firm had revenue of $126.64 million for the quarter, compared to analyst estimates of $123.55 million. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business’s revenue for the quarter was up 26.7% on a year-over-year basis. Analysts anticipate that Twist Bioscience will post -1.52 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In related news, insider Dennis Cho sold 949 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $128,494.60. Following the completion of the sale, the insider directly owned 62,840 shares in the company, valued at $8,508,536. This represents a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 1,007 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total value of $136,347.80. Following the sale, the senior vice president owned 105,625 shares of the company’s stock, valued at approximately $14,301,625. This represents a 0.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TWST. BlackRock Inc. acquired a new position in Twist Bioscience during the 2nd quarter worth approximately $600,191,000. William Blair Investment Management LLC acquired a new stake in Twist Bioscience in the second quarter valued at approximately $223,722,000. Bank of America Corp DE acquired a new stake in Twist Bioscience in the second quarter valued at approximately $94,922,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience during the first quarter worth $22,563,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Twist Bioscience during the second quarter worth $19,722,000.

Key Headlines Impacting Twist Bioscience

Investors following TWST have been watching these headlines:

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Further Reading

Analyst Recommendations for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.